within Pharmacolibrary.Drugs.ATC.R;

model R06AX28
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 13.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.652,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.035666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Rupatadine is a second-generation antihistamine and platelet-activating factor (PAF) antagonist used primarily for the symptomatic treatment of allergic rhinitis and urticaria. It is an orally active, non-sedating agent that is approved and available in many countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, after a single oral dose administration.</p><h4>References</h4><ol><li><p>Santamaria, E, et al., &amp; Valle, M (2021). Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study. <i>Clinical pharmacology : advances and applications</i> 13 115–122. DOI:<a href=&quot;https://doi.org/10.2147/CPAA.S312911&quot;>10.2147/CPAA.S312911</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34135645/&quot;>https://pubmed.ncbi.nlm.nih.gov/34135645</a></p></li><li><p>Nettis, E, et al., &amp; Vacca, A (2013). Rupatadine for the treatment of urticaria. <i>Expert opinion on pharmacotherapy</i> 14(13) 1807–1813. DOI:<a href=&quot;https://doi.org/10.1517/14656566.2013.813481&quot;>10.1517/14656566.2013.813481</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23806068/&quot;>https://pubmed.ncbi.nlm.nih.gov/23806068</a></p></li><li><p>Santamaría, E, et al., &amp; Potter, P (2018). Rupatadine oral solution for 2-5-year-old children with allergic rhinitis: a safety, open-label, prospective study. <i>Journal of asthma and allergy</i> 11 225–231. DOI:<a href=&quot;https://doi.org/10.2147/JAA.S164632&quot;>10.2147/JAA.S164632</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30214250/&quot;>https://pubmed.ncbi.nlm.nih.gov/30214250</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R06AX28;
